<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="abs0015">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="ulist0010">
   <list-item id="u0010">
    <label>•</label>
    <p id="p0010">Sequence comparison of SARS-CoV and SARS-CoV-2 for nsp12 (RdRp) and nsp14 (ExoN) show near structural &amp; functional identity.</p>
   </list-item>
   <list-item id="u0015">
    <label>•</label>
    <p id="p0015">Base &amp; ribose modifications of GS-441524 5′-TP 
     <italic>vs</italic> ATP point to specific discrimination mechanisms &amp; active site residues.
    </p>
   </list-item>
   <list-item id="u0020">
    <label>•</label>
    <p id="p0020">Lassa virus N &amp; SARS-CoV nsp14 ExoN domains allow modeling catalytically competent SARS-CoV-2 nsp14 Exonuclease.</p>
   </list-item>
   <list-item id="u0025">
    <label>•</label>
    <p id="p0025">RNA terminated with GS-441524 5′-MP at the 3′-end indicate a problematic accommodation at the nsp14 ExoN active site.</p>
   </list-item>
   <list-item id="u0030">
    <label>•</label>
    <p id="p0030">Anti-SARS-CoV-2 nucleoside analog design must consider balance between incorporation &amp; excision by nsp12 &amp; nsp14.</p>
   </list-item>
  </list>
 </p>
</abstract>
